

## Special Issue

# The Role of Hypofractionated Radiotherapy in Modern Oncology

### Message from the Guest Editors

Advances in current radiation oncology enabled more precise dose delivery with significant sparing of surrounding healthy tissues. Thus, the fear of late complications associated with a higher dose per fraction was drastically reduced. Moreover, radiobiological research suggested more complex interactions between various fraction doses with modern systemic treatments such as immunotherapy than those calculated using radiobiological models. Various regimens of hypofractionated radiotherapy were and are investigated in various clinical trials that confirmed their safety and efficacy. This Special Issue includes original reports and reviews that highlight biological and clinical aspects of hypofractionation in modern oncology. We also welcome studies regarding ultra-hypofractionation (SBRT, SRS). The main areas of interest are:

- The biological basis of hypofractionation;
- Novel indications for hypofractionated radiotherapy;
- The combination of hypofractionated regimens with systemic treatment and radiosensitizers.

---

### Guest Editors

Dr. Mateusz Spatek

Dr. Aleksandra Napieralska

Dr. Bartłomiej Tomasik

---

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/131245](https://mdpi.com/si/131245)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).